Immunomodulatory activity of SGI-110, a 5-aza-2-deoxycytidine-containing demethylating dinucleotide

Cancer Immunology, Immunotherapy

Volumn 62, Issue 3, 2013, Pages 605-614

  Coral, Sandra ^a   Parisi, Giulia ^b   Nicolay, Hugues J M G ^b   Colizzi, Francesca ^a   Danielli, Riccardo ^b   Fratta, Elisabetta ^a   Covre, Alessia ^b   Taverna, Pietro ^c   Sigalotti, Luca ^a   Maio, Michele ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

Cancer; DNA hypomethylating agent; Epigenetics; Immunotherapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; GAGE 1 2 ANTIGEN; GAGE 1 6 ANTIGEN; HLA ANTIGEN CLASS 1; INTERCELLULAR ADHESION MOLECULE 1; LACTATE DEHYDROGENASE; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 10; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MESSENGER RNA; NY ESO 1 ANTIGEN; SGI 110; SSX 1 5 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AZACITIDINE; DRUG DERIVATIVE; SGI-110;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER TESTIS ANTIGEN GENE; CELLULAR IMMUNITY; CONTROLLED STUDY; CPG ISLAND; CUTANEOUS MELANOMA; DNA METHYLATION; DRUG EFFECT; ENZYME ASSAY; ENZYME RELEASE; FLOW CYTOMETRY; GAGE 1 2 ANTIGEN GENE; GAGE 1 6 ANTIGEN GENE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; KIDNEY CARCINOMA; MAGE A1 ANTIGEN GENE; MAGE A10 ANTIGEN GENE; MAGE A2 ANTIGEN GENE; MAGE A3 ANTIGEN GENE; MAGE A4 ANTIGEN GENE; MESOTHELIOMA; NY ESO 1 ANTIGEN GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA CELL; SSX 1 5 ANTIGEN GENE; UPREGULATION; BIOSYNTHESIS; CYTOTOXICITY; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MELANOMA; METHODOLOGY; NEOPLASM; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; AZACITIDINE; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DNA METHYLATION; HUMANS; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MELANOMA; NEOPLASMS;

MLCS; MLOWN;

EID: 84877151648     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1365-7     Document Type: Article

References (24)

1. Sigalotti L, Fratta E, Coral S et al (2007) Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 212:330-344. doi: 10.1002/jcp.21066 (Pubitemid 47025622)
2. Fratta E, Sigalotti L, Colizzi F et al (2010) Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol 223:352-358. doi: 10.1002/jcp.22040
3. Fonsatti E, Nicolay HJ, Sigalotti L et al (2007) Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 13:3333-3338. doi: 10.1158/1078-0432.CCR-06-3091 (Pubitemid 46944920)
4. Coral S, Sigalotti L, Colizzi F et al (2006) Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J Cell Physiol 207:58-66. doi: 10.1002/jcp.20540
5. Sigalotti L, Fratta E, Coral S et al (2004) Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2-deoxycytidine. Cancer Res 64:9167-9171. doi: 10.1158/0008-5472.CAN-04-1442 (Pubitemid 39665532)
6. Schrump DS, Fischette MR, Nguyen DM et al (2006) Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12:5777-5785. doi: 10.1158/1078-0432.CCR-06-0669 (Pubitemid 44629609)
7. Weiser TS, Guo ZS, Ohnmacht GA et al (2001) Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 24:151-161 (Pubitemid 32183061)
8. Weiser TS, Ohnmacht GA, Guo ZS, Fischette MR, Chen GA, Hong JA, Nguyen DM, Schrump DS (2001) Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg 71:295-301 discussion-2 (Pubitemid 32102676)
9. Momparler RL (1985) Molecular, cellular and animal pharmacology of 5-aza-2-deoxycytidine. Pharmacol Ther 30:287-299 (Pubitemid 17207210)
10. Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, Redkar S, Jones PA (2007) Delivery of 5-aza-2-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 67:6400-6408. doi: 10.1158/0008-5472.CAN-07- 0251 (Pubitemid 47037524)
11. Issa JP, Roboz G, Rizzieri D, Faderl S, O'Connell C, Stock W, Tibes R, Griffiths E, Yee K, Chung W, Choy G, Oganesian A, Taverna P, Azab M, Kantarjian H (2012) Abstract LB-214: Interim results from a randomized Phase 1-2 first-in-human (FIH) study of PK/PD guided escalating doses of SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA) in relapsed/refractory MDS and AML. Cancer Res 72
12. Chuang JC, Warner SL, Vollmer D, Vankayalapati H, Redkar S, Bearss DJ, Qiu X, Yoo CB, Jones PA (2010) S110, a 5-Aza-2-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther 9:1443-1450. doi: 10.1158/1535-7163.MCT-09-1048
13. Altomonte M, Gloghini A, Bertola G, Gasparollo A, Carbone A, Ferrone S, Maio M (1993) Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res 53:3343-3348 (Pubitemid 23223307)
14. Coral S, Sigalotti L, Altomonte M et al (2002) 5-aza-2-deoxycytidine- induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 8:2690-2695 (Pubitemid 34856358)
15. Mutti L, Valle MT, Balbi B, Orengo AM, Lazzaro A, Alciato P, Gatti E, Betta PG, Pozzi E (1998) Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. Int J Cancer 78:740-749. doi: 10.1002/(SICI)1097-0215(19981209)78:6<740:AID- IJC12>3.0.CO;2-5 (Pubitemid 28530398)
16. Calabro L, Fonsatti E, Altomonte M, Pezzani L, Colizzi F, Nanni P, Gattei V, Sigalotti L, Maio M (2005) Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. J Cell Physiol 202:474-477. doi: 10.1002/jcp.20133 (Pubitemid 40041317)
17. Coral S, Sigalotti L, Gasparollo A, Cattarossi I, Visintin A, Cattelan A, Altomonte M, Maio M (1999) Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2-deoxycytidine (5-AZA-CdR). J Immunother 22:16-24 (Pubitemid 29042286)
18. Ausubel FM, Brent R, Kingston RE et al (1998) Current protocols in molecular biology. Wiley, New York
19. Li LC, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18:1427-1431 (Pubitemid 35414532)
20. Caballero OL, Chen YT (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100:2014-2021. doi: 10.1111/j.1349-7006. 2009.01303.x
21. Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F (2007) MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 256:139-189. doi: 10.1016/S0074-7696(07)56005-5 (Pubitemid 46109029)
22. Weidanz JA, Nguyen T, Woodburn T, Neethling FA, Chiriva-Internati M, Hildebrand WH, Lustgarten J (2006) Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol 177:5088-5097 (Pubitemid 44527579)
23. Lebedeva T, Dustin ML, Sykulev Y (2005) ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol 17:251-258. doi: 10.1016/j.coi.2005.04.008 (Pubitemid 40692659)
24. Coral S, Covre A, Jmg Nicolay H et al (2012) Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications. Br J Cancer. doi: 10.1038/bjc.2012.361